| Identification | Back Directory | [Name]
N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide Hcl | [CAS]
902135-91-5 | [Synonyms]
CS-266
AT 7519
AT7519 HCl
AT-7519(HCI)
AT7519; AT-7519
AT7519 HCl, >=99%
AT 7519 HCl salt
Light yellow solid
AT7519 (Hydrochloride)
AT 7519 hydrochloride salt
AT7519;AT-7519;AT 7519 HYDROCHLORIDE;AT-7519 HYDROCHLORIDE
4-(2,6-Dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide HCl
N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide Hcl
4-(2,6-Dichlorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide hydrochloride
N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride
4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic Acid Piperidin-4-ylamide Monohydrochloride
AT 7519
N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide hydrochloride | [Molecular Formula]
C16H18Cl3N5O2 | [MDL Number]
MFCD14636428 | [MOL File]
902135-91-5.mol | [Molecular Weight]
418.7 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
≥29.93 mg/mL in H2O; ≥43.3 mg/mL in DMSO with ultrasonic; ≥8.82 mg/mL in EtOH with ultrasonic | [form ]
crystalline solid |
| Hazard Information | Back Directory | [Description]
AT7519 is an ATP-competitive inhibitor of cyclin-dependent kinases (Cdks) with IC50 values of 210, 47, 100, 13, 170, and <10 nM for Cdk1, 2, 4, 5, 6, and 9, respectively.1 It is less potent against Cdk3 and Cdk7 and inactive against non-Cdk kinases save for GSK3β (IC50 = 89 nM).1 AT7519 demonstrates antiproliferative activity against a wide variety of human tumor cell lines (IC50s = 40-940 nM in vitro), inhibiting cell cycle progression and inducing apoptosis, and prevents tumor growth in human tumor xenograft models.1,2 AT7519 induces activation of GSK3β by down-regulating GSK3β phosphorylation, which contributes to AT7519-induced apoptosis.2 | [Uses]
4-(2,6-DichlorobenzoylaMino)-1H-pyrazole-3-carboxylic Acid Piperidin-4-ylaMide Monohydrochloride is used in the structure based design of a cyclin-dependant kinase CDK2 inhibitor.
|
|
|